

Attorney Docket No.: 5515.214-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

FILING UNDER 37 C.F.R. 1.53(b)

Box Patent Application  
Commissioner for Patents  
Washington, DC 20231

Express Mail Label No. **EL636736898US**  
Date of Deposit **June 22, 2001**

Sir:

This is a request for filing a **continuation** application under 37 C.F.R. 1.53(b)  
of

Applicant(s): Knudsen et al.

Title: Exendin Derivatives (As Amended)

60 pages of specification 1 sheet of abstract

3 sheets of Declaration and Power of Attorney

[x] The filing fee is calculated as follows:

Basic Fee:	\$710.00
Total Claims: $32 - 20 = 12 \times 18 =$	\$216.00
Independent Claims: $1 - 3 = 0 \times 80 =$	\$-0-
Total Fee:	\$926.00

Priority of Danish application no. 0274/98 filed on February 27, 1998 is claimed under 35 U.S.C. 119. A certified copy was filed with U.S. Serial No: 09/312,177 filed on May 14, 1999.

Priority of U.S. provisional application no. 60/084,357 filed on May 5, 1998 is claimed under 35 U.S.C. 119.

The benefit of application nos. PCT/DK99/00086 filed February 24, 1999 via the PCT and 09/312,177 filed on May 14, 1999 in the U.S. is claimed under 35 U.S.C. 120.

Please amend the specification as follows: At page 1, after the title, insert  
Cross-Reference to Related Applications


This application is a continuation of application serial no. 09/312,177 filed on May 14, 1999, which is a continuation of PCT/DK99/00086 filed February 24, 1999 and claims priority under 35 U.S.C. 119 of Danish application no. 0274/98 filed February 27, 1998, and U.S. provisional application no. 60/084,357 filed May 5, 1998, the contents of which are fully incorporated herein by reference.

Address all future communications to Reza Green, Esq., Novo Nordisk of North America, Inc., 405 Lexington Avenue, Suite 6400, New York, NY 10174-6401.

Please charge the required fee, estimated to be \$926, to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: 21 June 2001

  
Valeta A. Gregg, Reg. No. 35,127  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123



23650

PATENT TRADEMARK OFFICE

Attorney Docket No.: 5515.204-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Knudsen et al.

Serial No.: 09/312,177

Group Art Unit: 1653

Filed: May 14, 1999

Examiner: Mohamed

Confirmation No: 2248

For: Exendin Derivatives (As Amended)

**EXPRESS MAIL CERTIFICATE**

Commissioner for Patents  
Washington, DC 20231

Sir:

Express Mail Label No. EL636736898US

Date of Deposit June 21, 2001


I hereby certify that the following attached paper(s) or fee

1. Fee for Extension of Time (in duplicate)

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, DC 20231.

Sylvia Gonzalez

(Name of person mailing paper(s) or fee)



(Signature of person mailing paper(s) or fee)

Mailing Address:  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10017  
(212) 867-0123

09312177-062401  
TOTAL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

EXPRESS MAIL CERTIFICATE

Box Patent Application  
Commissioner for Patents  
Washington, DC 20231

Re: U.S. Patent Application for  
Title: Exendin Derivatives (As Amended)  
Applicants: Knudsen et al.

Sir:

Express Mail Label No. **EL636736898US**

Date of Deposit: **June 21, 2001**


I hereby certify that the following attached paper(s) or fee

1. Filing Under 37 C.F.R. 1.53(b) (in duplicate)
2. Patent Application
3. Copy of Executed Combined Declaration and Power of Attorney
4. Preliminary Amendment
5. Information Disclosure Statement
6. Form PTO-1449
7. Copy of Petition for Ext of Time (37 C.F.R. 1.136(a))

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington, DC 20231.

Sylvia Gonzalez

(Name of person mailing paper(s) or fee)



(Signature of person mailing paper(s) or fee)

Mailing Address:  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10017  
(212) 867-0123

09886311-062101

Attorney Docket No.: 5515.204-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Knudsen et al.

Serial No.: 09/312,177

Group Art Unit: 1653

Filed: May 14, 1999

Examiner: Mohamed

Confirmation No: 2248

For: Exendin Derivatives (As Amended)



**PETITION AND FEE FOR EXTENSION OF TIME (37 C.F.R. 1.136(a))**

Commissioner for Patents  
Washington, DC 20231

Express Mail: EL636736898US

Sir:


It is respectfully requested that the time for response to the Office Action dated January 3, 2001 be extended for a period of 3 months from April 3, 2001 to July 3, 2001. Applicant hereby petitions for such extension of time.

In the event that an extension of time is required, Applicant hereby petitions for such extension of time. The Commissioner of Patents is authorized to charge the required fee, if applicable, to Deposit Account No. 14-1447.

Please charge the required fee, estimated to be \$890, to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: 21 June 2001

  
Valeta A. Gregg, Reg. No. 35,427  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123



23650

PATENT TRADEMARK OFFICE

Attorney Docket No. 5515.204-US  
Patent Application entitled: "Exendin Derivatives"  
Applicants: Knudsen et al.  
U.S. Serial No: 09/312,177

The USPTO hereby acknowledges receipt of the following:  
1. Express Mail Certificate  
2. Petition & Fee For Extension of time (in duplicate)

VGre/SGon  
June 21, 2001

VIA US Express Mail, label no. EL636736898US

10996 U.S. PTO  
09/886311  
06/21/01